Local Coverage Determination (LCD)

Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)


Expand All | Collapse All
Proposed LCD
Proposed LCDs are works in progress that are available on the Medicare Coverage Database site for public review. Proposed LCDs are not necessarily a reflection of the current policies or practices of the contractor.

Document Note

Note History

Contractor Information

LCD Information

Document Information

Source LCD ID
Original ICD-9 LCD ID
Not Applicable
LCD Title
Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF)
Proposed LCD in Comment Period
Source Proposed LCD
Original Effective Date
For services performed on or after 12/16/2019
Revision Effective Date
For services performed on or after 09/01/2022
Revision Ending Date
Retirement Date
Notice Period Start Date
Notice Period End Date
AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Current Dental Terminology © 2023 American Dental Association. All rights reserved.

Copyright © 2023, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the American Hospital Association (AHA) copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.


Issue Description

Changes were made to correct typographical errors, update in-text citations and bibliography sources to AMA format. No changes were made to coverage.

Issue - Explanation of Change Between Proposed LCD and Final LCD

CMS National Coverage Policy

Title XVIII of the Social Security Act (SSA):

  • Section 1862(a)(1)(A) excludes expenses incurred for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.
  • Section 1833(e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

IOM Citations:

CMS Publication 100-04; Medicare Claims Processing Manual,

  • Chapter 4, Part B Hospital (Including Inpatient Hospital Part B and OPPS), Section 10 Hospital Outpatient Prospective Payment System (OPPS)
  • Chapter 13: Radiology Services and Other Diagnostic Procedures, 80 Supervision and Interpretation (S & I) Codes and Interventional Radiology

CMS IOM Publication 100-08, Medicare Program Integrity Manual,

  • Chapter 13, Local Coverage Determinations, Section 13.5.4 Reasonable and Necessary Provision in an LCD

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

The decision for treatment should take into consideration the local and general extent of the disease, the spinal level involved the severity of pain experienced by the patient as well as his or her neurologic condition, previous treatments and their outcomes, the general state of health, and life expectancy.

Percutaneous Vertebroplasty or Vertebral Augmentation including cavity creation is not to be considered a prophylactic procedure for osteoporosis of the spine. It also should not be used for chronic back pain of long-standing duration, even if associated with old compression fractures, unless pain is localized to a specific chronic fracture and medical therapy has failed.

Percutaneous vertebroplasty (PVP) is a therapeutic, interventional neurosurgical and radiological procedure that consists of the percutaneous injection of a biomaterial, methyl methacrylate, into a lesion of a thoracic or lumbar vertebral body. The procedure is utilized for pain relief and bone strengthening of weakened vertebral bodies. The procedure is performed under fluoroscopic guidance, although some prefer the use of computed tomography (CT) with fluoroscopy for needle positioning and injection assessment. An intraosseous venogram is sometimes performed before cement injection to determine whether the needle is positioned within a direct venous anastomosis to the central or epidural veins, to minimize extravasation into venous structures. Conscious sedation with additional local anesthesia (1% lidocaine) is generally utilized; however, patients who experience difficulties with ventilation or are unable to tolerate prone position during the procedure may require general anesthesia or deep sedation with airway and ventilation support. The methyl methacrylate is injected into the vertebral body until resistance is met or until cement reaches the posterior wall.

Percutaneous Vertebral Augmentation Percutaneous vertebral augmentation (PVA) is a minimally invasive procedure for the treatment of compression fractures of the vertebral body. The procedure includes the creation of a cavity, which results in fracture reduction along with an attempt to restore vertebral body height and alignment. Using imaging guidance x-rays, incisions are made and a probe is placed into the vertebral space in the location of the fracture. The collapsed vertebral body is drilled and a device, which displaces, removes, or compacts the compressed area of the vertebrae, is used to create a cavity prior to injection of the bone filler (polymethylmethacrylate) (PMMA).

Osteoporotic Conditions
Painful, debilitating, osteoporotic vertebral collapse/compression fractures, that have not responded to non-surgical management (e.g. narcotic and/or non-narcotic medication, physical therapy modalities) with or without methods of immobility (e.g. bed rest, bracing).

Both PVP and PVA will be considered reasonable and necessary for osteoporotic conditions when ALL of the following criteria are met:

  • Acute (< 6 weeks) or subacute (6-12 weeks) osteoporotic VCF (T1 – L5) based on symptom onset, and documented by recent (within 30 days) advanced imaging (bone marrow edema on MRI or bone-scan/SPECT/CT uptake)1-3, 10,25,27 and
  • The beneficiary is symptomatic and is hospitalized with severe pain (Numeric Rating Scale [NRS] or visual Analog Scale [VAS] pain score ≥ 8)4-7 or is non-hospitalized with moderate to severe pain (NRS or VAS ≥ 5) despite optimal non-surgical management (NSM)8 with one of the following:
    • Worsening pain or
    • Stable to improved pain (but NRS or VAS ≥ 5) when 2 or more of the following are present:
      • Progression of vertebral body height loss
      • >25% vertebral body height reduction
      • Kyphotic deformity
      • Severe impact of VCF on daily functioning (Roland Morris Disability Questionnaire (RDQ) > 17)
      • Steroid-induced fractures
      • Reinforcement or stabilization of vertebral body prior to surgery
  • Continuum of Care
    All patients presenting with vertebral compression fractures (VCF) should be referred for evaluation of bone mineral density and osteoporosis education for subsequent treatment as indicated and instructed to take part in an osteoporosis prevention/treatment program.8

Malignant Vertebral Fractures
Osteolytic vertebral metastasis or myeloma with severe back pain related to a destruction of the vertebral body, not involving the major part of the cortical bone.

  1. Painful osteolytic metastasis
  2. Multiple myeloma with painful vertebral body involvement

Traumatic Compression Fractures
Trauma, even minor falls, can produce a spine fracture. Many of these injuries will never require surgery, but major fractures can result in serious long-term problems unless treated promptly and properly. These severe injuries frequently result in spinal instability, with a high risk of spinal cord injury and pain, which can produce a spine fracture. WPS is reinstating coverage of PVA as reasonable and necessary for the following traumatic conditions.

  1. Stable and/or unstable burst fractures
  2. Wedge compression fractures
  3. Fracture-dislocations that occur following auto accidents or falls from height

Exclusion criteria for any patient considered for percutaneous vertebroplasty or vertebral augmentation2,5,8-10:

  1. Absolute contraindication
    • Current back pain is not primarily due to the identified acute VCF(s).
    • Osteomyelitis, discitis, or active systemic infection
  2. Relative contraindication
    • Greater than three vertebral fractures per procedure
    • Allergy to bone cement or opacification agents
    • Uncorrected coagulopathy
    • Spinal instability
    • Myelopathy from the fracture
    • Neurologic deficit
    • Neural impingement
    • Fracture retropulsion/canal compromise
    • Pregnancy
Summary of Evidence

Osteoporotic Compression Fractures
Osteoporosis (and low bone mass) affects 50 percent of people over 50 years of age, or over 50 million people in the United States. Its primary impact, fractures (also called fragility or low-trauma fractures), occurs secondary to normal activity (e.g., bending, coughing, lifting, fall from a standing height), and eventually occurs in 50% of women and 20% of men. VCFs constitute one-quarter of osteoporotic fractures,6 often at the midthoracic (T7-T8) and thoracolumbar junction (T12-L1). They may cause significant acute and chronic pain, leading to complications of impaired mobility comparable to a hip fracture (pneumonia, loss of bone and muscle mass, incidental falls, deep venous thrombosis, depression, and isolation).10 Medicare claims data shows an 85% 10-year mortality following a VCF diagnosis.11 Under-diagnosis and under-treatment may exacerbate morbidity and mortality.8 Vertebral augmentation provides a significant mortality benefit over nonsurgical management with a low number needed to treat (NNT).43

Treatment options for symptomatic osteoporotic VCF range from NSM (anti-osteoporosis therapy, analgesics, limited activity/bed rest, back brace, physical therapy) to PVA (PVP and PKP). PVP involves the percutaneous injection of bone cement under image guidance into the VCF. PKP adds balloon tamponade within the fractured vertebral body to create a low-pressure cavity prior to cement injection. Both treatments aimed to immobilize the fracture, reduce pain, and improve alignment.

Successful small European series introduced PVP into the United States in 1993; by 2007 encouraging preliminary observational data led to medical society endorsement and clinical acceptance in painful osteoporotic VCFs refractory to medical management. Subsequent early open-label randomized controlled trials (RCTs), including the Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures (VERTOS) trial,11 the Fracture Reduction Evaluation (FREE) trial,12,13 VERTOS II14 and others, found a benefit of vertebral augmentation over non-surgical management.

VERTOS II was a multicenter RCT that compared PVP and NSM of acute (< 6 weeks) osteoporotic VCF in patients with moderate to severe pain (VAS ≥ 5).14 Among 202 patients, the primary endpoint of pain relief at 1 month and 1 year was greater after PVP (-5.2/-5.7) than after NSM (-2.7/-3.7) (p < 0.001). Secondary outcomes, including RDQ and Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO), were similarly improved. The main limitation in the VERTOS II trial was the lack of blinding. Subsequent analysis of the medical cohort showed that 60% achieved sufficient (VAS ≤ 3) pain relief, most within 3 months.15 The authors acknowledged that despite the VERTOS II results, “clinicians still do not know how to best treat their patients,” but conclude that pending further RCTs, PVP may be justified in patients with insufficient pain relief after 3 months of conservative treatment.15

The lack of blinding made the early open-label RCTs, vulnerable to placebo effect. However, in 2009, 2 high profile, methodologically controversial (e.g., non-rigorous patient selection) double-blinded RCTs, found no benefit of PVP over a “sham” procedure (pedicle periosteal bupivacaine injection).16,17 Ever since, there has been a lack of consensus on the appropriate management of osteoporotic VCF, particularly the role of PVA.6,8 Medicare claims data shows that among over 2 million VCF patients, PVA was performed in 20% in 2005, peaked at 24% in 2007-2008, and declined to 14% in 2014, a 42% decrease.10 Lower PVA utilization was associated with a 4% increase in propensity-adjusted mortality risk (p < 0.001). Subsequent major RCTs, described below, have attempted to address the perceived shortcomings of these 2 negative studies (primarily more stringent selection criteria and choice of control).

The Vertebroplasty for Acute Painful Osteoporotic Fractures (VAPOUR) double-blinded RCT was designed to compare acute fracture (< 6 weeks) PVP with a sham procedure (subcutaneous, not periosteal, infiltration) for patients with severe pain (NRS ≥ 7).5 Among 120 randomized patients, the primary endpoint (NRS score < 4 by 14 days) was achieved in 44% and 21% of PVP and sham patients, respectively (p = 0.011), and durable to 6 months. Mean height loss at 6 months was 36% greater in the control group (63% vs. 27%). Hospital inpatients constituted 57% of study patients; among this group, median length of stay was reduced by 5.5 days in the PVP group. In addition to a focus on the acute, severely painful VCF, this study also concentrated on delivering greater cement volumes than prior studies. The authors conclude that PVP is superior to true placebo control of severe pain in VCFs of less than 6 weeks.

VERTOS IV used the same inclusion criteria as VERTOS II, but was a double-blinded comparison of PVP with a sham procedure (pedicle periosteal infiltration).7 Among the 180 randomized patients, although the reduction in VAS score was clinically (> 1.5 points) and statistically significant up to 12 months in both groups (5.00 at 12 months in the PVP group vs. 4.75 in the sham group), reductions in VAS scores did not differ between groups (p = 0.48). The authors conclude, “the results suggest that periosteal infiltration alone in the early phase provides enough pain relief with no need for additional cementation.” They recommend the “pragmatic approach” of first use of “periosteal infiltration during natural healing” and “cementation only in a selected subgroup of patients with insufficient pain relief after this early phase.” They also highlight a subgroup that may warrant earlier PVP per the VAPOUR trial (hospital inpatients with more comorbidity and severe pain).

The 2018 multicenter, prospective, uncontrolled, EVOLVE study of 354 Medicare-age patients with acute or subacute (≤ 4 mo.) painful (NRS ≥ 7) VCF (all but 8 osteoporotic), found statistical improvement in NRS, Oswestry Disability Index (ODI), Short Form-36 Questionnaire Physical Component Summary (SF-36v2 PCS), and EuroQol-5-Domain (EQ-SD) out to 12 months.18 The authors conclude that “kyphoplasty is a safe, effective, and durable procedure for treating patients with painful VCF due to osteoporosis.”

Hirsch, et al,43 is a claims-based analysis of national registries and insurance datasets that indicates a significant mortality benefit for patients with vertebral compression fractures who receive vertebral augmentation. Both vertebroplasty and kyphoplasty modalities conferred a prominent mortality benefit over nonsurgical management in the analysis of the US Medicare registry, with a low number needed to treat. The calculations based on this data base resulted in a low number needed to treat to save 1 life at 1 year and at 5 years. This analysis of >2,000,000 patients with vertebral compression fracture (VCF) revealed that only 15 patients need to be treated to save 1 life at 1 year. This large dataset analysis suggests that vertebral augmentation provides a significant mortality benefit over nonsurgical management with a low number needed to treat (NNT).

Malignant Compression Fractures
Rastogi, et al,19 is a peer reviewed article outlining the use of vertebral augmentation for compression fractures caused by malignant disease. Vertebroplasty or kyphoplasty is used as the principal palliative treatment for painful compression fractures caused by malignant disease. Vertebral augmentation provides rapid onset of pain relief and significant improvement in function, quality of life, and vertebral stability.

Mansoorinasab, et al,20 is a peer reviewed article updating new methods to determine the influence and the long-term consequences of percutaneous vertebroplasty (PVP) in the treatment of painful vertebral fractures (VFs) in metastatic patients of multifarious cancer of various sites on the spine. In patients with vertebral metastasis, PVP is considered a successful method for providing fast pain control, preventing most spinal cord compression, and vertebral collapse. The results of the peer review state that PVP is safe, feasible, reliable, effective, and useful procedure, a minimally invasive treatment, and a significant tool for reduction of pain.

Health Quality Ontario performed a systematic literature search for studies on vertebral augmentation of cancer-related vertebral compression fractures.21 The objective was to evaluate the effectiveness and safety of percutaneous image-guided vertebroplasty and kyphoplasty for palliation of cancer-related vertebral compression fractures. The data was compiled into categories of pain intensity, analgesic use, pain-related disability and physical performance, and health-related quality of life and patient satisfaction. In all of the clinical studies researched, patients that had either vertebroplasty or kyphoplasty, had high pain intensity levels (Visual Analogue Scale [VAS] ≥ 7.0) pre-procedure which were reduced post-procedurally to mild to low pain intensity levels (VAS < 4.0). Patients that were in the vertebroplasty group, reported change in analgesics, either discontinuation or a dose reduction. Patients from the kyphoplasty group infrequently reported analgesic use after the procedure. Both groups of patients showed improvement with pain-related disability and physical performance. The number of patients that required orthopedic braces or wheelchairs was significantly reduced after the procedures, as well as the number of patients that were bedridden or immobile. The health-related quality of life for both groups of patients was improved and remained improved at 1-year follow up. Both vertebroplasty and kyphoplasty rapidly reduced pain intensity levels in cancer patients with spinal fractures that were refractory to conservative care, usually bed rest and opioids. Both of these procedures were associated with a low-risk safety profile.

Kircelli, et al,22 is a 12 month retrospective clinical study of 72 patients (mean age of 78.93±8.77 years) with malignant vertebral compression fractures who underwent balloon kyphoplasty to investigate clinical results. Vertebral compression fractures due to bone metastases have limited treatment options which include bone-strengthening with cement and supportive care. Patients with metastatic vertebral compression fractures have reported reduced pain and improved functionability and quality of life post percutaneous kyphoplasty. In this study, the mean follow-up period was 18.91±3.71 months and mean bone mineral density (BMD) values were 3.19±0.46. The kyphosis angle (KA), vertebral height ratio (VHR), visual analog scale (VAS), and Oswerty disability Index (ODI) were compared pre and post balloon kyphoplasty. The KA decreased from 13.45±6.73 to 8.55±1.55, the VHR increased from 55.75±12.82% to 74.27±10.54, the VAS decreased from 8.11±0.83 to 2.55±1.16, and the ODI decreased from 65.51±7.32 to 25.18±4.37 at the 12th postoperative month, respectively (p<0.001). Post-procedural pain decreased significantly with a mean cement volume of 4.6±1.3ml. The authors conclude that percutaneous kyphoplasty is an effective method for reducing pain and disability in patients with vertebral compression fractures due to metastases thereby improving patient quality of life. Kyriakou, et al,23 is a review statement from the International Myeloma Working Group (IMWG) on the use of cement augmentation with percutaneous vertebroplasty and percutaneous kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma (MM). A majority of MM patients develop spinal osteolysis, which can result in painful vertebral compression fractures impacting quality of life and overall well-being. Pain associated with vertebral compression fractures can be disabling causing progressive deformities and resulting in significant chronic pain. Treatment of malignant vertebral compression fractures with balloon kyphoplasty (BKP) and percutaneous vertebroplasty (PV) is directed towards rapid pain reduction, keeping the patient ambulatory with a normal level of function in a relatively short period of time. The IMWG concludes the use of cement augmentation is an effective way to stabilize the spinal column and indicates balloon kyphoplasty (BKP) and percutaneous vertebroplasty (PV) allows the majority of patients the ability to return to a near normal level of function in a relatively short period of time by significantly reducing back pain and decreasing the use of pain relief. Further, the consensus statement from the IMWG states “multiple myeloma patients with significant pain at a fracture site should be offered a balloon kyphoplasty or percutaneous vertebroplasty procedure and the procedure should be performed within 4-8 weeks unless there are medical contraindications”.

Multi-Jurisdictional Contractor Advisory Committee (CAC) Meeting
After review of highly graded evidence-based literature from the years 2004 -2018, the opinions amongst the CAC Advisory Committee (CAC) members and the Subject Matter Experts (SME) varied on many of the proposed questions regarding the strength of evidence for the treatment of osteoporotic vertebral compression fractures with vertebroplasty and kyphoplasty. Multiple pieces of literature were discussed to determine if osteoporotic vertebral compression fractures receiving intervention treatment during the acute or subacute timeframes were supported. Also discussed were if current literature and quality of evidence addressed an acute, subacute or chronic fracture time frame, and if highly graded evidence existed for supporting conservative, non-interventional treatment. Topics within the discussion reviewed strength of evidence regarding pain relief, overall opioid usage, quality of life, mobility as well as mortality risk. CAC members and SMEs discussed the need for further research trials to strengthen existing data as others felt the benefits of these procedures have been proven in evidence-based literature from trials that have already been performed.

Analysis of Evidence (Rationale for Determination)

Whether or when to use PVA for osteoporotic VCF has been very controversial since publication of the two negative 2009 RCTs. At the time, some national organizations withdrew (Australia Medical Services Advisory Committee)6 or severely curbed (American Academy of Orthopaedic Surgeons)24 endorsement. Others continued recommending PVA in select patients. The National Institute for Health and Care Excellence (NICE) recommends PVA in patients “who have severe ongoing pain after a recent, unhealed vertebral fracture despite optimal pain management and in whom the pain has been confirmed to be at the level of the fracture by physical examination and imaging”.4 In a 2014 consensus statement, the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS), Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spin Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS) considered PVA a proven medically appropriate therapy for treatment of painful VCFs refractory to brief (24 hrs.) nonoperative medical therapy.1 The 2017 Cardiovascular and Interventional Radiologic Society of Europe (CIRSE) guideline notes that while the evidence for PVP has been conflicting, based on recent data “it seems clear that PVP offers significant pain reduction in patients with acute VCFs after short (<3 wks.) failed medical therapy.2

A 2018 Cochrane review of 21 trials of PVA for osteoporotic VCF “does not support a role for vertebroplasty for treating acute or subacute osteoporotic vertebral fractures in routine practice",17 though its methodology has been criticized.25 A 2019 systematic review and meta-analysis by the American Society for Bone and Mineral Research (ASBMR) Task Force concluded: “Vertebroplasty does not work to relieve pain from the fracture, and kyphoplasty should generally only be done in the context of a placebo-controlled clinical trial”.20 Based on the uncertainty of benefit, citing both the recent Cochrane analysis and the VERTOS IV results, UpToDate recommends reserving PVA “for patients with incapacitating pain from acute and subacute VCFs who are unable to taper parenteral opioids or transition to oral opioids within seven days of admission or have intolerable side effects from opioid therapy”.28

The benefit of PVA is supported by the significantly higher 5-year mortality risk for VCF in Medicare patients after a decline in utilization.11 In a recent systematic review of evidence-based guidelines for the management of osteoporotic VCF, 3 of 4 guidelines recommended PVA.19 In 2018, a multispecialty expert panel (orthopedic and neurosurgeons, interventional [neuro] radiologists and pain specialists), endorsed vertebral augmentation for select patients, in a clinical care pathway (developed using the RAND/UCLA Appropriateness Method), based on 7 variables (pain duration and evolution, acute fracture by advanced imaging, kyphotic deformity, degree and progression of vertebral height loss, and impact on daily functioning).10 Whether subgroups of patients might benefit more from vertebroplasty or kyphoplasty requires further study.6

A review of the 14 published RCTs that examined the role of VA in osteoporotic VCF concluded: “While the RCT data are conflicting, there are patients with acute fractures causing significant pain and disability who can derive benefit with respect to improvement in pain outcomes, reduction in narcotic usage and reduced length of hospital stay”.45 In a meta-analysis of 16 studies with mortality as an outcome, 8 reported mortality benefit in VA, 7 reported no benefit, and 1 reported mixed results.46 The analysis found that VA provided a 22% mortality benefit over NSM at 10 years. However, the authors note the potential for “a strong selection bias in the selection of healthier patients for VA that was not captured by the analysis.” They conclude that VA “remains a controversial treatment” and “should be offered in carefully selected patients.”

In summary, the premise of weight-bearing fracture immobilization, to limit pain and deformity, has prima facie validity on first principles. Superimposed is the recent trend toward immediate, focused, surgical immobilization, and away from prolonged, general immobilization (e.g., casting, bracing, bedrest) and prolonged systemic pain management (e.g., opioid analgesics), particularly in the elderly. The preponderance of evidence (studies, national and society guidelines, systematic reviews, multispecialty panel clinical care pathway, and Medicare claims data) favors consideration of early PVA in select patients (moderate to severe and disabling pain due to acute osteoporotic VCF confirmed by physical examination and advanced imaging findings). However, in addition to timely fracture treatment, also warranted is increased emphasis on ensuring the continuum of care and preventing medical under treatment of the overarching systemic disease, of which VCF is a symptom.47

Malignant Compression Fractures
Percutaneous vertebroplasty (PV) and balloon kyphoplasty (BKP) procedures have played a major role in the effective treatment of painful malignant compression fractures refractory to conservative care. Vertebroplasty procedures have been shown to provide rapid pain control and improved overall quality of life. After careful review of the literature, vertebral augmentation for malignant compression fractures is a reasonable and necessary procedure providing rapid pain control with a decrease in the need for analgesics, improvement in pain related disability and physical performance, and improved vertebral stability. The literature reviewed supports the clinical utility, the clinical validity and is relevant to the Medicare population. Therefore, coverage of PV and BKP will be added for the treatment of painful malignant compression fractures refractory to conservative care.

Traumatic Compression Fractures
WPS received multiple comments primarily concerning the denial of claims when PVA is performed for conditions related to trauma and malignancy. Our data supported the findings stated by the commenters. Since WPS had previously covered PVA for these conditions, we are reinstating coverage in this revision of the LCD.

Proposed Process Information

Synopsis of Changes
Changes Fields Changed
Associated Information
Sources of Information
Open Meetings
Meeting Date Meeting States Meeting Information
Contractor Advisory Committee (CAC) Meetings
Meeting Date Meeting States Meeting Information
MAC Meeting Information URLs
Proposed LCD Posting Date
Comment Period Start Date
Comment Period End Date
Reason for Proposed LCD
Requestor Information
This request was MAC initiated.
Requestor Name Requestor Letter
View Letter
Contact for Comments on Proposed LCD

Coding Information

Bill Type Codes

Code Description

Revenue Codes

Code Description


Group 1

Group 1 Paragraph


Group 1 Codes



ICD-10-CM Codes that Support Medical Necessity

Group 1

Group 1 Paragraph:


Group 1 Codes:



ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

Group 1 Paragraph:


Group 1 Codes:



Additional ICD-10 Information

General Information

Associated Information

Please refer to the Local Coverage Article: Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) (A57752) for documentation requirements that apply to the reasonable and necessary provisions outlined in this LCD.

Sources of Information

Chandra, R.V., Yoo, A. J., & Hirsch, J.A. (2013). Vertebral augmentation: update on safety, efficacy, cost effectiveness and increased survival? Pain Physician, 16, 309-320.

Lamy, O., Uebelhart, B., & Aubry-Rozier, B. (2014). Risks and benefits of percutaneous vertebroplasty or kyphoplasty in the management of osteoporotic vertebral fractures. Osteoporosis International, 25, 807-819.

Tan, H.Y., Wang, L. M., Zhao, L., Liu, Y.L., & Song, R.P. (2015). A prospective study of percutaneous vertebroplasty for chronic painful osteoporotic vertebral compression fracture. Pain Research & Management, 20 (1), 8-11.

Wang, H., & et al. (2015). Comparison of percutaneous vertebroplasty and balloon kyphoplasty for the treatment of single level vertebral compression fractures: a meta-analysis of the literature. Pain Physician, 18, 209-221.

  1. Barr JD, Jensen ME, Hirsch JA, et al. Position statement on percutaneous vertebral augmentation: a consensus statement developed by the Society of Interventional Radiology (SIR), American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS), American College of Radiology (ACR), American Society of Neuroradiology (ASNR), American Society of Spine Radiology (ASSR), Canadian Interventional Radiology Association (CIRA), and the Society of NeuroInterventional Surgery (SNIS). J Vasc Interv Radiol. 2014;25(2):171-181.
  2. Tsoumakidou G, Too CW, Koch G, et al. CIRSE Guidelines on Percutaneous Vertebral Augmentation. Cardiovasc Intervent Radiol. 2017;40(3):331-342.
  3. McConnell CT, Jr., Wippold FJ, 2nd, Ray CE, Jr., et al. ACR appropriateness criteria management of vertebral compression fractures. J Am Coll Radiol. 2014;11(8):757-763.
  4. National Institute for Health and Care Excellence (NICE). Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures. National Institute for Health and Care Excellence.
  5. Clark W, Bird P, Gonski P, et al. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10052):1408-1416.
  6. Chandra RV, Maingard J, Asadi H, et al. Vertebroplasty and Kyphoplasty for Osteoporotic Vertebral Fractures: What Are the Latest Data? AJNR Am J Neuroradiol. 2018;39(5):798-806.
  7. Firanescu CE, de Vries J, Lodder P, et al. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ. 2018;361:k1551.
  8. Hirsch JA, Beall DP, Chambers MR, et al. Management of vertebral fragility fractures: A clinical care pathway developed by a multispecialty panel using the RAND/UCLA Appropriateness Method. Spine J. 2018.
  9. National Guideline Clearinghouse (NGC). ACR Appropriateness Criteria® radiologic management of vertebral compression fractures. 2010. Revised 2018.
  10. Ong KL, Beall DP, Frohbergh M, Lau E, Hirsch JA. Were VCF patients at higher risk of mortality following the 2009 publication of the vertebroplasty "sham" trials? Osteoporos Int. 2018;29(2):375-383.
  11. Voormolen MH, Mali WP, Lohle PN, et al. Percutaneous vertebroplasty compared with optimal pain medication treatment: short-term clinical outcome of patients with subacute or chronic painful osteoporotic vertebral compression fractures. The VERTOS study. AJNR Am J Neuroradiol. 2007;28(3):555-560.
  12. Wardlaw D, Cummings SR, Van Meirhaeghe J, et al. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): A randomised controlled trial. Lancet. 2009;373(9668):1016-1024.
  13. Boonen S, Van Meirhaeghe J, Bastian L, et al. Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. J Bone Miner Res. 2011;26(7):1627-1637.
  14. Klazen CA, Lohle PN, de Vries J, et al. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): An open-label randomised trial. Lancet. 2010;376(9746):1085-1092.
  15. Venmans A, Klazen CA, Lohle PN, Mali WP, van Rooij WJ. Natural history of pain in patients with conservatively treated osteoporotic vertebral compression fractures: Results from VERTOS II. AJNR Am J Neuroradiol. 2012;33(3):519-521.
  16. Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361(6):557-568.
  17. Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med. 2009;361(6):569-579.
  18. Beall DP, Chambers MR, Thomas S, et al. Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures: The EVOLVE Trial. Neurosurg. 2019;84:169-178.
  19. Rastogi R, Patel T, Swarm R. Vertebral Augmentation for Compression Fractures Caused by Malignant Disease. J Natl Compr Cancer Network. 2010;8(9):1095-1102.
  20. Mansoorinasab M, Abdolhoseinpour H. A review and update of vertebral fractures due to metastatic tumors of various sites to the spine: Percutaneous vertebroplasty. Interv Med Appl Sci. 2018;10(1):1-6.
  21. Health Quality Ontario. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review. Ont Health Technol Assess Serv. 2016;16(11):1-202.
  22. Kircelli A, Coven I. Percutaneous Balloon Kyphoplasty Vertebral Augmentation for Compression Fracture Due to Vertebral Metastasis: A 12-Month Retrospective Clinical Study in 72 Patients. Med Sci Monit. 2018;24:2142-2148.
  23. Kyriakou C, Molloy S, Vrionis F, et al. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: A consensus statement from the International Myeloma Working Group (IMWG). Blood Cancer J. 2019;9(3):27.
  24. McGuire R. AAOS Clinical Practice Guideline: The Treatment of Symptomatic Osteoporotic Spinal Compression Fractures. J Am Acad Orthop Surg. 2011;19(3):183-184.
  25. Buchbinder R, Johnston RV, Rischin KJ, et al. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev. 2018;4:CD006349.
  26. Clark W, Bird P, Diamond T, Gonski P, Gebski V. Cochrane vertebroplasty review misrepresented evidence for vertebroplasty with early intervention in severely affected patients. BMJ Evid Based Med. 2019.
  27. Denaro V, Longo UG, Maffulli N, Denaro L. Vertebroplasty and kyphoplasty. Clin Cases in Miner and Bone Metab. 2009;6(2):125-130.
  28. Rosen HN, Walega DR. Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment. UpToDate. 2018.
  29. Parreira PCS, Maher CG, Megale RZ, March L, Ferreira ML. An overview of clinical guidelines for the management of vertebral compression fracture: A systematic review. Spine J. 2017;17(12):1932-1938.
  30. Ebeling PR, Akesson K, Bauer DC, et al. The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. J Bone Miner Res. 2019;34(1):3-21.
  31. Chandra RV, Meyers PM, Hirsch JA, et al. Vertebral augmentation: Report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery. J Neurointerv Surg. 2014;6(1):7-15.
  32. Anselmetti GC, Bernard J, Blattert T, et al. Criteria for the appropriate treatment of osteoporotic vertebral compression fractures. Pain Physician. 2013;16(5):E519-530.
  33. Grohs JG, Matzner M, Trieb K, Krepler P. Minimal invasive stabilization of osteoporotic vertebral fractures. J Spinal Disord Tech. 2005;18(3)238-242.
  34. Jensen ME, McGraw JK, Cardella JF, Hirsch JA. Position Statement on Percutaneous Vertebral Augmentation: A consensus statement developed by the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, American Association of Neurological Surgeons/Congress of Neurological Surgeons and American Society of Spine Radiology. Am J Neuroradiol. 2007;28(8):1439-1443.
  35. Lieberman IH, Dudeney S, Reinhardt MK, Bell G. Initial outcome and efficacy of “kyphoplasty” in the treatment of osteoporotic vertebral compression fractures. Spine. 26(14):1631-1638.
  36. Robinson Y, Heyde CE, Forsth P, Olerud C. Kyphoplasty in osteoporotic vertebral compression fractures-Guidelines and technical considerations. J Orthop Surg Res. 2011;6:43.
  37. Tanner SB. Back pain, vertebroplasty and kyphoplasty: Treatment of osteoporotic vertebral compression fractures. J Rheum Dis. 2003;52(2).
  38. Wong C, McGirt M. Vertebral compression fractures: A review of current management and multimodal therapy. J Multidiscip Healthc. 2013;6:205-214.
  39. Baker B . New technique eases painful vertebral fractures. OB/GYN News. 2000.
  40. Kochan JP. Percutaneous Vertebroplasty and Kyphoplasty. Medscape. 2009. Updated November 04, 2015.
  41. ACR-ASNR-ASSR-SIR-SNIS Practice Parameter For The Performance Of Vertebral Augmentation. American College of Radiology (ACR). Revised 2017 (Resolution 16).
  42. National Guideline Clearinghouse (NGC). ACR Appropriateness Criteria® radiologic management of vertebral compression fractures. 2010. Revised 2018.
  43. Hirsch JA, Chandra RV, Carter NS, Beall D, Frohbergh M, Ong K. Number Needed to Treat with Vertebral Augmentation to Save a Life. Am J Neuroradiol. 2019:1-5. Doi:10.3174/ajnr.A6367.
  44. Hansen EJ, Simoney A, Carreon L, Rousing R, Tropp H, Andersen MO. Vertebroplasty vs. SHAM for Treating Osteoporotic Vertebral Compression Fractures: A Double Blind RCT (VOPE). Integr J Orthop Traumatol.2019;2(4)1-6.
  45. De Leacy R, Chandra RV, Barr JD, et al. The evidentiary basis of vertebral augmentation: a 2019 update. J Neurointerv Surg. 2020.
  46. Hinde K, Maingard J, Hirsch JA, Phan K, Asadi H, Chandra RV. Mortality Outcomes of Vertebral Augmentation (Vertebroplasty and/or Balloon Kyphoplasty) for Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis. Radiol. 2020;00:1-8. Doi:10.1148/radiol.2020191294.
  47. Conley RB, Adib G, Adler RA, et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. J Bone Miner Res. 2020;35(1):36-52.

Revision History Information

Revision History Date Revision History Number Revision History Explanation Reasons for Change
09/01/2022 R3

09/01/2022 Review completed 7/19/2022. Under Coverage Guidance Osteoporotic Conditions corrected T5 to T1 in the first bullet point to read “Acute (< 6 weeks) or subacute (6-12 weeks) osteoporotic VCF ( T1 – L5)>…”. Typographical and grammatical errors corrected throughout. In-text citations and bibliography references corrected to AMA format. No change in coverage.

  • Provider Education/Guidance
07/01/2021 R2

07/01/2021 Under Limitations for clarification removed the statement (Can have NONE of the following) as Absolute and Relative limitations are listed.

  • Provider Education/Guidance
10/01/2020 R1

10/01/2020 Revised the title to reflect expanded coverage and removed “Osteoporotic”. Expanded coverage under Coverage Indications, Limitations, and/or Medical Necessity, Summary of Evidence and Analysis of Evidence to revise Osteoporotic section and to include malignant and traumatic vertebral fractures. Updated bibliography. Please refer to A57479 Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Vertebral Compression Fracture (VCF) for additional ICD-10 codes for conditions now covered by this LCD. Review completed 08/31/2020.

  • Provider Education/Guidance

Associated Documents

Related National Coverage Documents
Public Versions
Updated On Effective Dates Status
08/23/2022 09/01/2022 - N/A Currently in Effect You are here
Some older versions have been archived. Please visit the MCD Archive Site to retrieve them.


  • Compression fracture
  • Vertebral fracture
  • Fracture spine
  • Malignant fractures
  • Traumatic vertebral fractures

Read the LCD Disclaimer